Process for obtaining insulin precursors from reaction mixtures resulting from the folding of insulin precursors from the corresponding S-sulfonates

• US 4,801,684 A
• Filed: 09/02/1986
• Issued: 01/31/1989
• Est. Priority Date: 01/19/1985
• Status: Expired due to Term

• Current Assignee: Hoechst Aktiengesellschaft (Sanofi )
• Original Assignee: Hoechst Aktiengesellschaft (Sanofi )
• Inventors: Grau, Ulrich
• Primary Examiner(s): SCHAIN, HOWARD
• Application Number:
  US06/924,850
• Time in Patent Office: 882 Days
• Field of Search: 530/303, 530/304, 530/305, 514/3, 514/4
• US Class Current: 530/303
• CPC Class Codes: C07K 14/625 Extraction from natural sources
• CPC Class Codes: Y10S 930/26 Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Abstract

A process for the preparation of insulin precursors of the formula (I) ##STR1## in which R is hydrogen or the presequence P_m --Q_n --, in which P is a sequence of naturally occurring amino acids with m being from 0 to 50, Q are basic natural amino acids, and n is an integer from 1 to 4, Y represents --Lys^B29 --Z^B30 --, in which Z denotes Ala, Thr or Ser, and the bridge extending from A-1 to A-21 is an insulin A-chain, the bridge extending from B-1 to B-30 represents an insulin B-chain, and X is a bridge which is bonded to the insulin A-chain at the amino group of A-1 and is bonded to the insulin B-chain at the ε-amino group of B-29-- in which case it is bonded to the free bond of Z^B30 OH-- or at the carboxyl group of B-30, from reaction mixtures which result from folding of insulin precursors from S-sulfonates of the formula (II) ##STR2## in which R, X and Y have the abovementioned meanings, which comprises the false recombinants contained in the reaction mixture being precipitated by adjustment of the reaction mixture to pH 4 to 6, the precipitate being removed in customary manner and converted by sulfitolysis into the S-sulfonate of the formula (II), and the latter then being subjected to renewed folding.

Claims

1. A process for the preparation of correctly-recombined insulin precursors of the formula (I) ##STR4## in which R is hydrogen or the presequence P_m --Q_n --, in which P is a sequence of naturally occurring amino acids with m being from 0 to 50, Q are basic natural amino acids, and n is an integer from 1 to 4, Y represents --Lys^B29 --Z^B30 --, in which Z denotes Ala, Thr or Ser, and the bridge extending from A-1 to A-21 is an insulin A-chain, the bridge extending from B-1 to B-30 represents an insulin B-chain, and X is a bridge which is bonded to the insulin A-chain at the amino group of A-1 and is bonded to the insulin B-chain at the ε

-amino group of B-29--in which case it is bonded to the free bond of Z^B30 OH--or at the carboxyl group of B-30, comprising the steps of

folding, in a reaction mixture, S-sulfonates of the formula (II) ##STR5## in which R, X and Y have the abovementioned meanings, under conditions sufficient to correctly recombine the insulin precursors of formula (I),

precipitating false recombinants co-formed in the folding step by adjustment of the reaction mixture to pH 4 to 6,

removing the precipitate,

converting the precipitate by sulfitolysis into S-sulfonates of the formula (II), and

subjecting the sulfitolyzed S-sulfonates to folding under conditions sufficient to form the insulin precursors of formula (I).

2. The process as claimed in claim 1, wherein the reaction mixture contains, when the precipitate is formed, a physiologically acceptable surface-active substance effective to prevent the binding of correctly-recombined insulin precursors of formula (I) to co-formed false recombinants.

3. The process as claimed in claim 2, wherein the surface-active substance is a polymer of the formula R² --O--X_n --R³ (III), in which X_n is a chain of n members of the formula

4. The process as claimed in claim 3, wherein the polymer is added in an amount of 1 to 400, preferably 2 to 200 mg/l.

5. The process as claimed in claim 1, wherein the folding step is carried out in the presence of a physiologically acceptable surface-active substance effective to prevent the binding of correctly-recombined insulin precursors of formula (I) to co-formed false recombinants.

6. The process as claimed in claim 5, wherein an excess of mercaptan is used in the folding, and the recombined insulin precursors are reoxidized with oxygen.

7. The process as claimed in claim 2, wherein the folding step is carried out in the presence of a physiologically acceptable surface-active substance effective to prevent the binding of corectly-recombined insulin precursors of formula (I) to co-formed false recombinants.

8. The process as claimed in claim 3 wherein the folding step is carried out in the presence of a physiologically acceptable surface-active substance effective to prevent the binding of correctly-recombined insulin precursors of formula (I) to co-formed false recombinants.

9. The process as claimed in claim 4 wherein the folding step is carried out in the presence of a physiologically acceptable surface-active substance effective to prevent the binding of correctly-recombined insulin precursors of formula (I) to co-formed false recombinants.

10. The process as claimed in any one of claims 1, 2, 3, 4, 5 or 6 wherein the folding is carried out using a ratio of --SH groups to --SSO₃^- groups of 1 to 5, in an aqueous medium, at a pH of 7 to 11.5 and a S-sulfonate insulin precursor concentration of up to 10 mg per ml, and at a temperature of 0°

to 37°

C.

11. The process as claimed in claim 7, further comprising at least one of the following process modifications:

the reaction is carried out (1) with a S-sulfonate insulin precursor concentration of 0.2 to 1 mg per ml of aqueous medium, (2) at a pH of 9.5 to 11, (3) at a reaction temperature of 2°

to 10°

C., (4) with a reaction time of 5 to 20 hours, (5) using a ratio of --SH groups to --SSO₃^- groups of 2 to 3, and (6) with exclusion of oxygen to a large extent.

12. The process as claimed in any one of claims 1, 2, 3, 4, 5 or 6 wherein the mercaptan is 2-mercaptoethanol, thioglycolic acid or its methyl ester, 3-mercapto-1,2-propane-diol or 3-mercaptopropionic acid or its esters.